NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report.

NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report.

The NOA-03 trial explored high-dose methotrexate alone in 37 patients with primary central nervous system lymphoma. The overall median survival was 25 months. After 4 years, the rate of leukoencephalopathy in patients surviving more than 12 months was 58% with and 10% without whole-brain radiotherap...

Bibliografski detalji
Glavni autori:	Herrlinger, U, Küker, W, Uhl, M, Blaicher, H, Karnath, H, Kanz, L, Bamberg, M, Weller, M
Format:	Journal article
Jezik:	English
Izdano:	2005

Slični predmeti

German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma.
od: Herrlinger, U, i dr.
Izdano: (2002)

Primary central nervous system (CNS) lymphoma in immunocompetent patients.
od: Plasswilm, L, i dr.
Izdano: (2002)

Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients.
od: Küker, W, i dr.
Izdano: (2005)

Primary central nervous system lymphomas (PCNSL): MRI response criteria revised.
od: Küker, W, i dr.
Izdano: (2005)

MRI features of primary central nervous system lymphomas at presentation.
od: Bühring, U, i dr.
Izdano: (2001)

Ocular manifestation of primary nervous system lymphoma: what can be expected from imaging?
od: Küker, W, i dr.
Izdano: (2002)

PCV salvage chemotherapy for recurrent primary CNS lymphoma.
od: Herrlinger, U, i dr.
Izdano: (2000)

Primary CNS lymphoma in the spinal cord: clinical manifestations may precede MRI detectability.
od: Herrlinger, U, i dr.
Izdano: (2002)

Radiomic prediction for durable response to high‐dose methotrexate‐based chemotherapy in primary central nervous system lymphoma
od: Haoyi Li, i dr.
Izdano: (2024-09-01)

First-line therapy with temozolomide induces regression of primary CNS lymphoma.
od: Herrlinger, U, i dr.
Izdano: (2002)

Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma
od: Xianggui Yuan, i dr.
Izdano: (2024-02-01)

Transient encephalopathy after intrathekal methotrexate chemotherapy: diffusion-weighted MRI.
od: Küker, W, i dr.
Izdano: (2005)

High-Dose Methotrexate for the Treatment of Relapsed Central Nervous System Erdheim-Chester Disease
od: Prahlad Ho, i dr.
Izdano: (2014-01-01)

Treatment of Recurrent Posttransplant Lymphoproliferative Disorder of the Central Nervous System with High-Dose Methotrexate
od: Clare J. Twist, i dr.
Izdano: (2013-01-01)

Leptomeningeal metastasis: survival and prognostic factors in 155 patients.
od: Herrlinger, U, i dr.
Izdano: (2004)

Sequential high‐dose methotrexate and cytarabine administration improves outcomes in real‐world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance
od: Maciej Tatarczuch, i dr.
Izdano: (2024-08-01)

Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma
od: Julia Wendler, i dr.
Izdano: (2025-01-01)

Progressive multifocal leukoencephalopathy: cidofovir therapy in three patients with underlying hematological disease.
od: Herrlinger, U, i dr.
Izdano: (2003)

Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience
od: Adam Suleman, i dr.
Izdano: (2022-12-01)

Acridios del NOA IV
od: Sonia Z. Turk
Izdano: (2020-10-01)

Acridoideos del NOA. V
od: Sonia Z. Turk
Izdano: (2020-10-01)

Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients
od: Rudy Birsen, i dr.
Izdano: (2018-07-01)

Primary CNS lymphoma: Diagnosis and treatment
od: Herrlinger, U, i dr.
Izdano: (2003)

The pharmacogenetics of methotrexate in inflammatory bowel disease.
od: Herrlinger, K, i dr.
Izdano: (2005)

P1223: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZRMA REGIMEN（ZANUBRUTINIB, RITUXIMAB, METHOTREXATE AND CYTARABINE)
od: Y. Tang
Izdano: (2022-06-01)

PB2315: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZR OR ZRM REGIMEN (ZANUBRUTINIB, RITUXIMAB, METHOTREXATE)
od: Yue Teng, i dr.
Izdano: (2023-08-01)

P1217: INTRATHECAL METHOTREXATE PROPHYLAXIS AND CENTRAL NERVOUS SYSTEM RELAPSE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH INTENSIFIED R-ACVBP STRATEGY
od: L. Renaud, i dr.
Izdano: (2022-06-01)

The role of upfront lenalidomide maintenance for primary central nervous system lymphoma following first‐line methotrexate treatment: A retrospective study
od: Yan Zhang, i dr.
Izdano: (2024-05-01)

Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study
od: Zhiyong Zeng, i dr.
Izdano: (2024-09-01)

Oral methotrexate in ulcerative colitis.
od: Cummings, JR, i dr.
Izdano: (2005)

Treatment of primary central nervous system lymphomas
od: I. V. Cherkashina, i dr.
Izdano: (2021-06-01)

Relapsed isolated CNS lymphoma treated with radiotherapy and intrathecal methotrexate followed by high‐dose intravenous methotrexate, rituximab, and temozolomide: A case report
od: Ikhwan Rinaldi, i dr.
Izdano: (2024-03-01)

P1145: PRELIMINARY RESULTS OF PENPULIMAB COMBINED WITH RMA(RITUXIMAB, METHOTREXATE, AND CYTARABINE) FOR NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
od: Haorui Shen, i dr.
Izdano: (2023-08-01)

The cortical substrate of visual extinction.
od: Karnath, H, i dr.
Izdano: (2003)

Central nervous system involvement in non-Hodgkin's lymphoma
od: M T Kutluk, i dr.
Izdano: (1988-01-01)

COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE
od: Giuseppina Massini, i dr.
Izdano: (2009-11-01)

COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE
od: Stefan Hohaus, i dr.
Izdano: (2009-12-01)

III° Jornadas de Historia Reciente del NOA
od: Alicia Gartner
Izdano: (2017-11-01)

Adverse Oral Reactions Associated with Low Doses of Methotrexate
od: N. V. Izmozherova, i dr.
Izdano: (2020-12-01)

Prevention and management of secondary central nervous system lymphoma
od: Sabela Bobillo, i dr.
Izdano: (2022-11-01)